Stocks › FATE
FATE THERAPEUTICS INC
FATE·Nasdaq·
United States·USD
United States·USD$2.29
-0.14 (-5.76%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
FATE
FATE THERAPEUTICS INC · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
FATES&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of FATE by members of U.S. Congress · 1 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Daniel S. GoldmanHouse · D · NY |
FATEFATE THERAPEUTICS INC · Stock |
Sale $1,001 - $15,000 |
Feb 24, 2023 | Jan 31, 2023 | Filing ↗ |
Whale Activity
Position changes in FATE reported for 2026-06-30 by 9 tracked institutional filers
- Increased6
- New1
- Held0
- Decreased1
- Closed0
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 7.3M | $19.7M | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.5M | $12.3M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.4M | $12.0M | increased |
| TWO SIGMA INVESTMENTS, LP | 3.6M | $9.7M | increased |
| RENAISSANCE TECHNOLOGIES LLC | 3.0M | $8.1M | increased |
| MILLENNIUM MANAGEMENT LLC | 2.4M | $6.6M | new |
| CITADEL ADVISORS LLC | 993.3K | $2.7M | increased |
| Point72 Asset Management, L.P. | 442.2K | $1.2M | increased |
| Parametrica Management Ltd | 18.5K | $50K | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by FATE insiders, by quarter · Form 4
Recent Insider Transactions
640 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| TAHL CINDYSee Remarks | Sale | −38.8K | $2.46 | $95K | Aug 4, 2026 | Form 4 ↗ |
| Valamehr BahramPresident and CEO · Director | Sale | −43.9K | $2.46 | $108K | Aug 4, 2026 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Sale | −25.6K | $1.88 | $48K | May 20, 2026 | Form 4 ↗ |
| Valamehr BahramPresident and CEO · Director | Sale | −28.9K | $1.88 | $54K | May 20, 2026 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Option exercise | +44.4K | $1.05 | $47K | May 6, 2026 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Option exercise | +122.2K | $1.32 | $161K | May 6, 2026 | Form 4 ↗ |
| EPSTEIN ROBERT SDirector | Option exercise | +25.0K | $1.69 | $42K | May 5, 2026 | Form 4 ↗ |
| RASTETTER WILLIAM HDirector | Option exercise | +25.0K | $1.69 | $42K | May 5, 2026 | Form 4 ↗ |
| Green JeremyDirector · 10% owner | Other | +9.0M | $0.00 | $0 | Apr 20, 2026 | Form 4 ↗ |
| Green JeremyDirector · 10% owner | Other | −9.0M | $0.00 | $0 | Apr 20, 2026 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Grant / award | +100.0K | $0.00 | $0 | Jan 15, 2026 | Form 4 ↗ |
| Adawi KamalChief Financial Officer | Grant / award | +25.0K | $0.00 | $0 | Jan 15, 2026 | Form 4 ↗ |
| Valamehr BahramPresident and CEO · Director | Grant / award | +335.0K | $0.00 | $0 | Jan 15, 2026 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Sale | −10.6K | $1.06 | $11K | Jan 9, 2026 | Form 4 ↗ |
| Valamehr BahramPresident and CEO · Director | Sale | −5,190 | $1.07 | $6K | Jan 9, 2026 | Form 4 ↗ |
| Adawi KamalChief Financial Officer | Grant / award | +75.0K | $0.00 | $0 | Oct 20, 2025 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Sale | −9,037 | $1.06 | $10K | Aug 4, 2025 | Form 4 ↗ |
| Valamehr BahramPresident and CEO · Director | Sale | −14.5K | $1.06 | $15K | Aug 4, 2025 | Form 4 ↗ |
| TAHL CINDYSee Remarks | Grant / award | +70.0K | $0.00 | $0 | Jan 15, 2025 | Form 4 ↗ |
| Bressi Jerome CharlesSee Remarks | Grant / award | +65.0K | $0.00 | $0 | Jan 15, 2025 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding FATE · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 3.2M | $8.6M | 0.00% | Jun 30, 2026 |
| VANGUARD STRATEGIC EQUITY FUND VANGUARD HORIZON FUNDS | 3.0M | $8.0M | 0.07% | Jun 30, 2026 |
| iShares Russell 2000 ETF iSHARES TRUST | 2.7M | $3.2M | 0.00% | Mar 31, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.1M | $3.1M | 0.00% | Jun 30, 2026 |
| BRUCE FUND Bruce Fund, Inc. | 989.2K | $2.7M | 0.71% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund BlackRock Funds | 876.1K | $2.5M | 0.05% | May 29, 2026 |
| VANGUARD STRATEGIC SMALL-CAP EQUITY FUND VANGUARD HORIZON FUNDS | 786.8K | $2.1M | 0.07% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 629.8K | $1.7M | 0.02% | Jun 30, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 559.3K | $1.6M | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 535.8K | $1.5M | 0.00% | May 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list FATE's shares (CUSIP 31189P102), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming FATE THERAPEUTICS INC as client
No lobbying filings found naming FATE THERAPEUTICS INC as the client.
Government Contracts
Federal awards to FATE THERAPEUTICS INC · USAspending
No federal contract awards found for FATE THERAPEUTICS INC.
U.S. Patents
Recent USPTO applications naming FATE THERAPEUTICS INC
No USPTO patent applications found for FATE THERAPEUTICS INC.
Annual Financials
From FATE's 10-K filings · XBRL
No annual XBRL figures on record for FATE. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in FATE's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 8.01, 9.01Other eventsSep 28, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 13, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 15, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJun 4, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 13, 2026
EDGAR ↗
About FATE THERAPEUTICS INC
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersSAN DIEGO, CA
SEC CIK0001434316 ↗